Elidel & Cancer
The U.S. Food and Drug Administration (FDA) has issued a warning about the potential risk of cancer in patients using Elidel (pimecrolimus) and Protopic (tacrolimus), products applied directly to the skin. These medications are prescribed for patients with atopic dermatitis (eczema) and for patients who are unresponsive to, or intolerant of other treatments. The FDA based its warning on studies in which three different species of animals developed cancer following exposure to these drugs, whether applied to the skin or given by mouth. These studies were conducted at higher doses than generally used by patients, with the risk of cancer increasing with increasing drug dose and duration of use.
At Pogust Braslow & Millrood, protecting our clients is our primary goal. We recognize that drug companies are under an obligation to warn doctors about the known risks of their products; in some circumstances, they are also required to warn consumers about the risks of their products. When they fail to do so, they may be held responsible for the injuries or deaths that are the consequence of their inaction.
If you or a loved one has developed skin cancer while taking Elidel, you should immediately contact the attorneys at Pogust Braslow & Millrood, where Protecting Consumers Is Our Primary Goal. Just fill out this form, click here to send us an email or call us at (610) 941-4204.
|
